European Journal of Cancer
Volume 39, Issue 9 , Pages 1310-1317 , June 2003

Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines

  • H.H.J Backus

      Affiliations

    • Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    • Present address: Crucell Holland B.V., Leiden, The Netherlands.
    • ,
  • D Wouters

      Affiliations

    • Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    • ,
  • C.G Ferreira

      Affiliations

    • Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    • ,
  • V.M.M van Houten

      Affiliations

    • Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    • ,
  • R.H Brakenhoff

      Affiliations

    • Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    • ,
  • H.M Pinedo

      Affiliations

    • Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    • ,
  • G.J Peters

      Affiliations

    • Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31-20-4442633; fax: +31-20-4443844

Received 11 July 2002 ,Revised 17 December 2002 ,Accepted 28 February 2003.

References 

  1. Carreras CW, Santi DV. The catalytic mechanism and structure of thymidylate synthase. Ann. Rev. Biochem. 1995;64:721–762
  2. Danenberg PV, Malli H, Swenson S. Thymidylate synthase inhibitors. Semin. Oncol. 1999;26:621–631
  3. Schmoll HJ, Buchele T, Grothey A, et al.  Where do we stand with 5-fluorouracil?. Semin. Oncol. 1999;26:589–605
  4. Moertel CG. Chemotherapy of gastrointestinal cancer. N. Engl. J. Med. 1994;330:1136–1142
  5. Jackman AL, Taylor GA, Gibson W, et al.  ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumour cell growth in vitro and in vivo (a new agent for clinical study). Cancer Res. 1991;51:5579–5586
  6. Webber S, Bartlett CA, Boritzki TJ, et al.  AG337, a novel lipophilic thymidylate synthase inhibitor (in vitro and in vivo pre-clinical studies). Cancer Chemother. Pharmacol. 1996;37:509–517
  7. Shih C, Chen VJ, Gossett LS, et al.  LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57:1116–1123
  8. Cocconi G, Cunningham D, Van Cutsem E, et al.  Open, randomised, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J. Clin. Oncol. 1998;16:2943–2952
  9. Peters GJ, van Triest B, Backus HHJ, et al.  Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor Raltitrexed. Eur. J. Cancer. 2000;36:916–924
  10. Backus HHJ, Pinedo HM, Wouters D, et al.  Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates. Oncol. Res. 2000;12:231–239
  11. Nita ME, Nagawa H, Tominaga O, et al.  5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of bcl-2 family proteins. Br. J. Cancer. 1998;78:986–992
  12. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 1992;11:121–139
  13. Mesner P, Budihardjo I, Kaufman SH. Chemotherapy-induced apoptosis. Adv. Pharmacol. 1997;41:461–499
  14. Decaudin D, Marzo I, Brenner C, et al.  Mitochondria in chemotherapy-induced apoptosis: a prospective novel target of cancer therapy. Int. J. Oncol. 1998;12:141–152
  15. Kaufmann SH, Eamshaw WC. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 2000;256:42–49
  16. Houghton JA. Apoptosis and drug response. Curr. Opin. Oncol. 1999;11:475–481
  17. Friesen C, Fulda S, Debatin K-M. Cytotoxic drugs and the CD95 pathway. Leukemia. 1999;13:1854–1858
  18. Houghton JA, Harwood FG, Tillman DM. Thymineless death in colon carcinoma cells is mediated via Fas signalling. Proc. Natl Acad. Sci. USA. 1997;94:8144–8149
  19. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases (structure, activation, substrates and functions during apoptosis). Ann. Rev. Biochem. 1999;68:383–424
  20. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 1999;59:1391–1399
  21. Harris CC. Structure and function of the p53 tumor suppressor gene (clues for rational cancer therapeutic strategies). J. Natl Cancer lnst. 1996;88:1442–1455
  22. Miyashita I, Krajewski M, Krajewska M, et al.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994;9:1799–1805
  23. Müller M, Wilder S, Bannasch O, et al.  P53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 1998;188:2033–2045
  24. O'Connor PM, Jackman J, Bae I, et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997;57:4285–4300
  25. Peters GJ, Backus HHJ, Freemantle S, et al.  Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim. Biophys. Acta. 2002;1587:194–205
  26. Pocard M, Chevillard S, Villaudy J, et al.  Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation. Oncogene. 1996;12:875–882
  27. Tamura T, Aoyama N, Saya H, et al.  Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Oncogene. 1995;11:1939–1946
  28. Flaman JM, Frebourg I, Moreau V, et al.  A simple p53 functional assay for screening cell lines, blood and tumors. Proc. Natl Acad. Sci. USA. 1995;92:3963–3967
  29. Sidransky O, Von Eschenbach A, Tsai YC, et al.  Identification of p53 gene mutations in bladder cancers and urine samples. Science. 1991;252:706–709
  30. Van Houten VM, Tabor MP, van den Brekel MW, et al.  Molecular assays for the diagnosis of minimal residual head-and-neck cancer (methods, reliability, pitfalls, and solutions). Clin. Cancer Res. 2000;6:3803–3816
  31. van Houten VM, van den Brekel MW, Denkers F, et al.  Molecular diagnosis of head and neck cancer. Recent Results Cancer Res. 2000;157:90–106
  32. Keepers YPAM, Pizao PE, Peters GJ, et al.  Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur. J. Cancer. 1991;27:897–900
  33. Ferreira CG, Span SW, Peters GJ, et al.  Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small-cell lung cancer cell line NCI-H460. Cancer Res. 2001;60:7133–7144
  34. Peters GJ, Wets M, Keepers YPAM, et al.  Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Int. J. Cancer. 1993;54:450–455
  35. Ferreira CG, Tolis C, Span SW, et al.  Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CG95/Apo1) signalling pathway. Clin. Cancer Res. 2000;6:203–212
  36. Backus HHJ, Dukers DF, van Groeningen CJ, et al.  5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. Ann. Oncol. 2001;12:209–216
  37. Bobrow MN, Harris ID, Shaughnessy KJ, et al.  Catalyzed reporter deposition, a novel method of signal amplification. I. Application for immunoassays. J. Immunol. Methods. 1989;125:279–285
  38. Curtin NJ, Harris AL, Aherne GW. Mechanism of cell death following thymidylate synthase inhibition (2′-deoxyuridine-5′-triphosphate accumulation, DNA damage, a growth inhibition following exposure to CB3717 and dipyridamole). Cancer Res. 1991;51:2346–2352
  39. Tonkinson JL, Marder P, Andis SL, et al.  Cell cyde effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother. Pharmacol. 1997;39:521–531
  40. Matsui SI, Arredondo MA, Wrzosek C, et al.  DNA damage and p53 induction, do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. Cancer Res. 1996;56:4715–4723
  41. Van Triest B, Pinedo HM, Giaccone G, et al.  Downstream molecular determinants of response to 5-fluorouracil and antifolate synthase inhibitors. Ann. Oncol. 2000;11:385–391
  42. Tillman DM, Harwood FG, Gibson AA, et al.  Expression of genes that regulate Fas signalling and Fas-mediated apoptosis in colon carcinoma cells. Cell Death Diff. 1998;5:450–457
  43. Adachi Y, Taketani S, Oyaizu H, et al.  Apoptosis of colorectal adenocarcinoma induced by 5-FU and/or IFNγ through caspase-3 and caspase-8. Int. J. Oncol. 1999;15:1191–1196
  44. Tillman DM, Petak I, Houghton JA. A Fas-dependent component in 5-Fluorouracil/Leucovorin-induced cytotoxicity in colon carcinoma cells. Clin. Cancer Res. 1999;5:425–430
  45. Ikebukuro K, Adachi Y, Toki J, et al.  Morphological change, loss of Δψm and activation of caspases upon apoptosis of colorectal adenocarcinoma induced by 5-FU. Cancer Lett. 2000;153:101–108

PII: S0959-8049(03)00204-1

doi: 10.1016/S0959-8049(03)00204-1

European Journal of Cancer
Volume 39, Issue 9 , Pages 1310-1317 , June 2003

Article Tools

* Image Usage & Resolution